Transcript How I Treat Instability in the Contact Athlete

40th Annual Meeting
Clinical Track Program
“Cradle to the Grave”
Issues in the Pediatric and Master’s Athlete
February 10-11, 2012
Jacksonville, Fl
2012 Clinical Track Supporters
Disclosure Statement
The Hawkins Foundation
Greenville Hospital System
DJO Surgical
Tornier
Breg
Euflexxa
Smith & Nephew
Cannon
Arthrocare
OttoBach
Disclosure Statement
Jason Folk, MD
Consultant for Smith&Nephew Endoscopy
Disclosure Statement:
Product / Unlabeled Use Discussion
Dr. Steven Sabo
Product: Tumor Necrosis Factor alpha inhibitors (class drugs)
examples below as reported in peer reviewed Rheumatology
literature case studies
Unlabeled use: Pigmented Villonodular Synovitis refractory to
Surgery
Product: adalimumab (Humira)
Unlabeled use: Pigmented Villonodular Synovitis refractory to
Surgery
Product: etanercept (Enbrel) and infliximab (Remicade)
Unlabeled use: Pigmented Villonodular Synovitis refractory to Surgery
Disclosure Statement
All other speakers/planners have no financial
relationships to disclose
Clinical Track Planning
Committee
Kyle Cassas, MD, FACSM
(Chair)
Sean Bryan, MD
Dave Sealy, MD
Franklin Sease, MD
(Vice Chair)
Heather Fullerton, MD
Chad Asplund, MD
Rob Hosey, MD
Kenneth Barnes, MD
Charles Lascano, MD
• Please thank our exhibitors and
clinical track supporters who make
this meeting possible!
• Please put your mobile devices on
vibrate or silent mode.
• We need your email address to
mail out certificates after the
meeting.
• CEU’s may also be available this
year.
Thanks to Cecilia Hanna
and
the Hawkins Foundation
for providing CME.
Clinical Reception will be held in
River Terrace 2
Friday-6:30-8:00pm
Presented by the Steadman
Hawkins Clinic of the Carolinas